EVHNYSEServices-Management ServicesFiscal year ends December 31
Evolent Health, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$4.48−0.09 (-1.97%)
Close on Oct 19, 2026
- Market cap
- $504.19M
- P/E (TTM)
- –
- Dividend yield
- –
Evolent Health, Inc. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Evolent Health Services Segment | $1.88B | $2.55B | $1.96B | $1.35B | $907.96M | $382.36M | $409.53M | – | – | – | 100.0% | -26.6% |
| Reportable segment | $1.88B | $2.55B | $1.96B | $1.35B | – | – | – | – | – | – | 100.0% | -26.6% |
| Services | – | – | – | – | – | $925.00M | $687.12M | $547.43M | $434.95M | $254.19M | – | – |
| True Health | – | – | – | – | – | $117.58M | $172.72M | $94.76M | $0 | $0 | – | – |
| Clinical Solutions | – | – | – | $944.51M | $598.14M | $542.28M | $278.22M | – | – | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Platform and operations services | – | – | – | – | $896.75M | $912.65M | $671.92M | $500.19M | $405.48M | $215.87M | – | – |
| Transformation services | – | – | – | – | $11.20M | $11.99M | $15.20M | $32.92M | $29.47M | $38.32M | – | – |
| Premiums | – | – | – | – | – | $117.38M | $171.74M | $93.96M | $0 | $0 | – | – |
| Services revenue | – | – | – | – | – | $905.06M | $674.64M | $533.11M | $434.95M | – | – | – |
By region
From the segment and revenue-disaggregation notes of Evolent Health's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.